Sangamo Therapeutics posts ST-503 nonclinical safety presentation for small fiber neuropathy

Sangamo Therapeutics, Inc.

Sangamo Therapeutics, Inc.

SGMO

0.00
  • Sangamo published nonclinical safety results for ST-503, an investigational AAV9 gene therapy designed to repress SCN9A (Nav1.7) for treatment of small fiber neuropathy.
  • Six-month GLP study in cynomolgus monkeys reported no dose-limiting toxicity following one-time intrathecal dosing at 10,000,000,000,000, 60,000,000,000,000, 90,000,000,000,000 vg/animal.
  • Pharmacology readouts at 6 months showed intended SCN9A repression in dorsal root ganglia, with activity also reported in trigeminal ganglia.
  • Mouse fertility and embryo-fetal development study using a surrogate AAV9 ZFR at 5,710,000,000,000 vg/kg found no test-article-related adverse effects.
  • Integration and germline assessments reported no evidence of AAV germline transmission to offspring, with liver integration profile described as low-level and polyclonal, supporting a low tumor-risk signal.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sangamo Therapeutics Inc. published the original content used to generate this news brief on May 12, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.